Two sequential tPA/DNase courses for noncommunicating loculated collections in pleural infection

Natalia Popowicz1,2, Francesco Piccolo3, Ranjan Shrestha4 & Y. C. Gary Lee2,4

1Pharmacy Department, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
2Centre for Asthma, Allergy & Respiratory Research, School of Medicine & Pharmacology, University of Western Australia, Perth, Western Australia, Australia
3Department of Medicine, Swan District Hospital, Perth, Western Australia, Australia
4Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Keywords
Deoxyribonuclease, empyema, fibrinolytics, pleural infection, tissue plasminogen activator.

Abstract
Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) therapy is being increasingly employed as an alternative to surgical intervention for the treatment of complicated parapneumonic effusions and empyema. Published cases are limited to one randomized control trial and few case reports. No data exist on employing sequential or repeated courses of intrapleural tPA/DNase to aid evacuation of separate collections in patients’ with a multiloculated pleural infection. This is the first report of successful use of sequential delivery of separate courses of intrapleural tPA/DNase to two noncommunicating infected pleural fluid collections within the same hemithorax of a patient. Our case confirms that prior treatment with tPA/DNase therapy does not preclude subsequent effective and safe use of this intrapleural treatment.

Introduction
Pleural infection is common and is associated with high morbidity. Treatment involves antibiotic therapy and pleural fluid drainage; however, thick and loculated pus often prohibits drainage and may necessitate surgical intervention [1]. Initial management of multiloculated empyemas involves chest tube insertion to evacuate the largest collection. Further tube thoracostomy may be needed for separate locules if infection persists.

Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) therapy has been shown in a randomized trial to enhance pleural fluid drainage in patients with complicated pleural infection, reducing length of hospitalization and need for surgery [2]. To date, outcomes from less than 50 published cases exist on intrapleural tPA/DNase therapy [2, 3]. No data exist on employing sequential or repeated courses of intrapleural tPA/DNase in the same patient.

We report the first successful treatment of multiloculated empyema by sequential delivery of two courses of intrapleural tPA/DNase to noncommunicating pleural pus collections within the same hemithorax of a patient.

Case Report
A previously well 17-year-old male presented with a productive cough, fever (38.4°C) and left-sided pleuritic chest pain. His chest radiograph (CXR) and subsequent computed tomography confirmed left lower lobe pneumonia and he was commenced on piperacillin/tazobactam. A repeat CXR and ultrasound on day (D) 5 identified a multiloculated pleural effusion. Analyses of the pleural aspirate confirmed a complicated parapneumonic effusion: pH 6.09, lactate dehydrogenase 71,300 U/L, protein 40 g/L but no microorganism was cultured. A chest tube (12F) was inserted under imaging guidance into the largest locule.

Although fever resolved, a rising leukocyte count and C-reactive protein (CRP) with residual pleural effusion on CXR suggested persistent infection (Figs. 1, 2). Antibiotic therapy was changed to meropenem. To facilitate drainage, tPA (10 mg) followed by DNase (5 mg) were instilled...
intrapleurally twice daily over 3 days, as per published protocols [2]. Prior to instillation, only 400 mL of pleural fluid had drained. Twenty-four hours after initiating tPA/DNase, 2075 mL was drained, and in total, 4050 mL were drained by 72 h. This was paralleled by a significant reduction in effusion size on CXR. A residual 5 × 7-cm anterolateral fluid collection, separate to the one treated with tPA/DNase was identified at D11 on pleural ultrasound. A therapeutic thoracentesis evacuated 300 mL of purulent fluid. His infection markers improved: white cell count 31.7 to 12.7 × 10⁹/L; CRP 470 to 170 mg/L and he was discharged on D13 with home intravenous antibiotics.

He re-presented on D16 with fever, worsening leukocytosis and re-accumulation of the previously aspirated anterolateral collection. A chest tube (12F) was inserted and 310 mL of purulent fluid was drained over 48 h. Fluid culture remained negative. Computed tomography confirmed optimal placement of the chest drain but a residual collection persisted. Given the success from the first course of tPA/DNase, the family and patient elected to repeat intrapleural therapy over surgery. Six doses of tPA/DNase were administered to the second collection. A further 550 mL of pleural fluid was drained over 72 h with resolution of sepsis: the fever resolved and both leukocytosis (23.8 to 8.2 × 10⁹/L) and CRP (130 to 13 mg/L) settled. No residual fluid was present on CXR or ultrasound when the tube was removed. The patient was discharged on oral antibiotics. He made an uneventful recovery and at 3-month follow-up had no respiratory symptoms or residual opacity on CXR.

**Discussion**

This is the first reported case of the use of successive courses of intrapleural tPA/DNase to separate noncommunicating pleural fluid collections. The initial course successfully drained the dominant collection with resolution of the infection indices. A separate and isolated locule was

---

**Figure 1.** White cell count, C-reactive protein and cumulative pleural fluid drained during hospital admission on days 1 to 13 and days 16 to 24. Horizontal arrows represent days of tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) administration.
Patients with pleural infection often have multiloculated effusions. Insertion of separate chest tubes is sometimes needed to evacuate noncommunicating collections. The use of tPA/DNase can breakdown adhesions and minimize such a need. Nonetheless, in some patients (like this case), walled off collections are separated in distant parts of the pleural cavity. Our case showed for the first time that different noncommunicating collections can be treated separately with successive courses of tPA/DNase therapy without complications, and surgery avoided.

Concerns remain on the safety and optimal regime of tPA/DNase therapy. The bleeding rates of intrapleural fibrinolytics use have been low in all large published series [2, 4]. Given the short systemic half-life of fibrinolytics, repeated administration should not pose significantly higher bleeding risks. Unlike streptokinase, administration of tPA does not induce the formation of antibodies against the drug and will not prohibit further courses of therapy. Our case confirms that prior treatment with tPA/DNase therapy probably does not preclude effective use of this intrapleural therapy in the future.

**Disclosure Statements**

Prof. Lee was a co-investigator of the MIST-2 study, which received unrestricted research funds from Roche UK.

Appropriate written informed consent was obtained for publication of this case report and accompanying images.

**Acknowledgments**

Y. C. G. Lee is a National Health and Medical Research Council (NHMRC) Career Development Fellow and receives project grant funding from the NHMRC, New South Wales Dust Disease Board, Sir Charles Gairdner Research Advisory Committee, Westcare and the Cancer Council of Western Australia. N. Popowicz receives funding support from an Australian Postgraduate Award.

**References**

1. Davies HE, Davies RJO, and Davies CWH. 2010. Management of pleural infection in adults: British Thoracic Society pleural disease guideline. Thorax 65(Suppl. 2): ii41–ii53.
2. Rahman NM, Maskell NA, West A, et al. 2011. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N. Engl. J. Med. 365(6):518–526.
3. Simpson G, Roomes D, and Reeves B. 2003. Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 58(4):365–366.
4. Maskell NA, Davies CW, Nunn AJ, et al. 2005. U.K. controlled trial of intrapleural streptokinase for pleural infection. N. Engl. J. Med. 352(9):865–874.